FDA Cracks Down Hard — 30 Telehealth Companies Warned Over Compounded Ozempic & Zepbound Copies
The FDA sent warning letters to 30 telehealth companies for false claims about compounded GLP-1 drugs like semaglutide and tirzepatide.
The FDA sent warning letters to 30 telehealth companies for false claims about compounded GLP-1 drugs like semaglutide and tirzepatide.
Hims & Hers jumps over 13% after HHS Secretary RFK Jr. told Joe Rogan he's pushing to make key peptides more accessible via compounding, potentially boosting the telehealth company's growth in wellness treatments.
Hims & Hers (HIMS) beat profit expectations in Q4 2025 with $2.35B full-year revenue (up 59%). 2026 forecast of $2.7-2.9B tops analyst views as the company expands globally after its cheap Wegovy copy plan backfired.
Hims & Hers Health is buying Eucalyptus, a top digital health company, in a deal worth up to $1.15 billion. This move helps bring easy, personalized online health care to more countries like Australia, Japan, UK, Germany, and Canada.
Danish pharma giant Novo Nordisk files patent lawsuit against telehealth company Hims & Hers for selling unauthorized versions of Wegovy and Ozempic weight-loss medications.
Hims & Hers Health stops selling its cheaper Wegovy copycat pill just two days after launch following FDA crackdown and Justice Department investigation into compounded weight-loss drugs.